Patent ID: 11884726
Assignee: PFIZER INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A  G | IPC A  C  G

Claim 7:
8. A method for treating ulcerative colitis in a patient comprising administering subcutaneously to the patient a dose of 22.5 mg of MAdCAM antagonist antibody comprising a light chain CDR1 of SEQ ID NO:11; a light chain CDR2 of SEQ ID NO:12; and a light chain CDR3 of SEQ ID NO:13; and
a heavy chain CDR1 of SEQ ID NO:14; a heavy chain CDR2 of SEQ ID NO:15; and a heavy chain CDR3 of SEQ ID NO:16,
once every 4 weeks for at least 12 weeks to achieve a clinical remission rate of at least about 10% compared to baseline, wherein the clinical remission rate is determined using a MAYO score or a sccai score.